Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.

Gumus M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., ÖZGÜROĞLU M., ...Daha Fazla

Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 4 - 08 Haziran 2021, cilt.39, (Özet Bildiri) identifier

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 39
  • Doi Numarası: 10.1200/jco.2021.39.15_suppl.9078
  • Basıldığı Ülke: ELECTR NETWORK
  • Trakya Üniversitesi Adresli: Evet